NFKB1 and acute respiratory distress syndrome: Findings from a series of cases suggested that both oral and IV administration of glutathione, along with glutathione precursors like N‐acetyl‐cysteine and α‐lipoic acid, could potentially offer a new therapeutic avenue for inhibiting nuclear factor kappa B (NF‐κB), managing cytokine storms, and addressing ARDS in individuals diagnosed with COVID‐19 pneumonia.51